103 related articles for article (PubMed ID: 8885674)
21. Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia.
Nosten F; Luxemburger C; Kyle DE; Gordon DM; Ballou WR; Sadoff JC; Brockman A; Permpanich B; Chongsuphajaisiddhi T; Heppner DG
Am J Trop Med Hyg; 1997 May; 56(5):526-32. PubMed ID: 9180603
[TBL] [Abstract][Full Text] [Related]
22. Follow-up of Gambian children recruited to a pilot safety and immunogenicity study of the malaria vaccine SPf66.
Bojang KA; Obaro SK; Leach A; D'Alessandro U; Bennett S; Metzger W; Ballou WR; Targett GA; Greenwood BM
Parasite Immunol; 1997 Dec; 19(12):579-81. PubMed ID: 9458470
[TBL] [Abstract][Full Text] [Related]
23. The development of malaria vaccines: SPf66--what next?
Tanner M; Alonso PL
Schweiz Med Wochenschr; 1996 Jul; 126(27-28):1210-5. PubMed ID: 8766632
[TBL] [Abstract][Full Text] [Related]
24. Assessment of the humoral and cell-mediated immunity against the Plasmodium falciparum vaccine candidates circumsporozoite protein and SPf66 in adults living in highly endemic malarious areas of Papua New Guinea.
Beck HP; Felger I; Kabintik S; Tavul L; Genton B; Alexander N; Bhatia KK; al-Yaman F; Hii J; Alpers M
Am J Trop Med Hyg; 1994 Sep; 51(3):356-64. PubMed ID: 7943557
[TBL] [Abstract][Full Text] [Related]
25. Evidence of HLA class II association with antibody response against the malaria vaccine SPF66 in a naturally exposed population.
Beck HP; Felger I; Barker M; Bugawan T; Genton B; Alexander N; Jazwinska E; Erlich H; Alpers M
Am J Trop Med Hyg; 1995 Sep; 53(3):284-8. PubMed ID: 7573714
[TBL] [Abstract][Full Text] [Related]
26. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania.
Acosta CJ; Galindo CM; Schellenberg D; Aponte JJ; Kahigwa E; Urassa H; Schellenberg JR; Masanja H; Hayes R; Kitua AY; Lwilla F; Mshinda H; Menendez C; Tanner M; Alonso PL
Trop Med Int Health; 1999 May; 4(5):368-76. PubMed ID: 10402973
[TBL] [Abstract][Full Text] [Related]
28. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
Rosas JE; Hernández RM; Gascón AR; Igartua M; Guzman F; Patarroyo ME; Pedraz JL
Vaccine; 2001 Aug; 19(31):4445-51. PubMed ID: 11483270
[TBL] [Abstract][Full Text] [Related]
29. An efficacy trial of the malaria vaccine SPf66 in Gambian infants--second year of follow-up.
Bojang KA; Obaro SK; D'Alessandro U; Bennett S; Langerock P; Targett GA; Greenwood BM
Vaccine; 1998 Jan; 16(1):62-7. PubMed ID: 9607010
[TBL] [Abstract][Full Text] [Related]
30. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres.
Rosas JE; Pedraz JL; Hernández RM; Gascón AR; Igartua M; Guzmán F; Rodríguez R; Cortés J; Patarroyo ME
Vaccine; 2002 Mar; 20(13-14):1707-10. PubMed ID: 11906756
[TBL] [Abstract][Full Text] [Related]
31. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States.
Gordon DM; Duffy PE; Heppner DG; Lyon JA; Williams JS; Scheumann D; Farley L; Stacey D; Haynes JD; Sadoff JC; Ballou WR
Am J Trop Med Hyg; 1996 Jul; 55(1):63-8. PubMed ID: 8702024
[TBL] [Abstract][Full Text] [Related]
32. The vaccine is dead--long live the vaccine.
Snounou G; Rénia L
Trends Parasitol; 2007 Apr; 23(4):129-32. PubMed ID: 17300988
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
[TBL] [Abstract][Full Text] [Related]
34. Synthetic vaccine update: applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization.
Bermúdez A; Reyes C; Guzmán F; Vanegas M; Rosas J; Amador R; Rodríguez R; Patarroyo MA; Patarroyo ME
Vaccine; 2007 May; 25(22):4487-501. PubMed ID: 17403557
[TBL] [Abstract][Full Text] [Related]
35. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
36. SPf66: research for development or development of research?
Alonso PL; Teuscher T; Tanner M
Vaccine; 1994 Feb; 12(2):99-101. PubMed ID: 8147103
[No Abstract] [Full Text] [Related]
37. Safety, immunogenicity and limited efficacy study of a recombinant Plasmodium falciparum circumsporozoite vaccine in Thai soldiers.
Brown AE; Singharaj P; Webster HK; Pipithkul J; Gordon DM; Boslego JW; Krinchai K; Su-archawaratana P; Wongsrichanalai C; Ballou WR
Vaccine; 1994 Feb; 12(2):102-8. PubMed ID: 8147091
[TBL] [Abstract][Full Text] [Related]
38. Malaria vaccine trials: the missing qualitative data.
Ferreira M
Immunol Cell Biol; 1996 Aug; 74(4):301-5. PubMed ID: 8872178
[TBL] [Abstract][Full Text] [Related]
39. An efficacy trial of a malaria vaccine in Gambian infants and comparison with insecticide-treated bednets.
D'Alessandro U
Ann Trop Med Parasitol; 1996 Aug; 90(4):373-8. PubMed ID: 8944081
[TBL] [Abstract][Full Text] [Related]
40. Analysis of multiple Plasmodium falciparum infections in Tanzanian children during the phase III trial of the malaria vaccine SPf66.
Beck HP; Felger I; Huber W; Steiger S; Smith T; Weiss N; Alonso P; Tanner M
J Infect Dis; 1997 Apr; 175(4):921-6. PubMed ID: 9086150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
